Black/African American patients with type 2 diabetes mellitus: Study design and baseline patient characteristics from a randomized clinical trial of linagliptin

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 17, 2012, Pages 2443-2452

  Thrasher, James ^a   Daniels, Kristen ^b   Patel, Sanjay ^c   Whetteckey, Jacqueline ^b  

^a Medical Investigations Inc   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c BOEHRINGER INGELHEIM LTD   (United Kingdom)

Author keywords

African American; Black; Diabetes; Linagliptin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LINAGLIPTIN; PLACEBO;

ADULT; AFRICAN AMERICAN; AGED; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; ERYTHRODERMA; FEMALE; GLUCOSE BLOOD LEVEL; HEART MUSCLE ISCHEMIA; HEMOGLOBIN BLOOD LEVEL; HISPANIC; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREATITIS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RASH; SELF REPORT; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES;

ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PURINES; QUINAZOLINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84869813774     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.740459     Document Type: Article

References (16)

1. The Black Population: 2010. 2010 Census Briefs. 2011. Available from: http://www.census. gov/prod/cen2010/briefs/c2010br-06.pdf [Last accessed 28 February 2012]
2. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. 2011. Available from: http://www.cdc. gov/diabetes/pubs/pdf/ndfs-2011.pdf [Last accessed 6 September 2012]
3. African Americans and Complications. Available from: http://www.diabetes. org/living-with-diabetes/complications/african-americans-and-complications.html [Last accessed 19 September 2011]
4. Marshall MC Jr. Diabetes in African Americans. Postgrad Med J 2005;81(962):734-40
5. Ten Facts about African Americans and Kidney Disease. Available from: http://www.kidney.org/news/newsroom/fs-new/10factsabtaframerkd.cfm [Last accessed 19 September 2011]
6. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diab Obes Metab 2011;13(1):7-18
7. Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diab Obes Metab 2011;13(3):258-67
8. Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diab Obes Metab 2011;13(1):65-74
9. Gomis R, Espadero RM, Jones R, et al. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diab Obes Metab 2011;13(7):653-61
10. Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 2011;28(11):1352-61
11. Overview of Race and Hispanic Origin: 2010. 2010 Census Briefs. 2011. Available from: http://www.census. gov/prod/cen2010/briefs/c2010br-02.pdf [Last accessed 3 October 2011]
12. Shavers-Hornaday VL, Lynch CF, Burmeister LF, Torner JC. Why are African Americans under-represented in medical research studies? Impediments to participation. Ethn Health 1997;2(1-2):31-45
13. Powell JH, Fleming Y, Walker-Mcgill CL, Lenoir M. The project IMPACT experience to date: increasing minority participation and awareness of clinical trials. J Natl Med Assoc 2008;100(2):178-87
14. Ard JD, Durant RW, Edwards LC, Svetkey LP. Perceptions of African-American culture and implications for clinical trial design. Ethn Dis 2005;15(2):292-9
15. Kennedy BM, Kumanyika S, Ard JD, et al. Overall and minority-focused recruitment strategies in the PREMIER multicenter trial of lifestyle interventions for blood pressure control. Contemp Clin Trials 2010;31(1):49-54
16. Project IMPACT (Increase Minority Participation and Awareness of Clinical Trials). Available from: http://impact. nmanet.org [Last accessed 5 October 2011]